The FDA expanded its approval of linaclotide to include pediatric patients aged 2 to 5 years with functional ...

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life changing therapies for people living with gastrointestinal (GI) and rare diseases, today ...

Phase 3 data support a lower age threshold for linaclotide, making it the first prescription therapy approved for functional constipation in patients ages 2 to 5.

Ironwood Pharmaceuticals (IRWD) announced on Wednesday that the Food and Drug Administration approved a label expansion for its AbbVie (ABBV)-partnered bowel disorder therapy Linzess to treat children ...

Linzess comes as an oral capsule in three strengths: 72 micrograms (mcg), 145 mcg, and 290 mcg. The appropriate dosage varies based on the condition being treated and the patient’s age. This ...

Inform your doctor of all medications, supplements, and health conditions that apply to you before taking Linzess to prevent possible interactions. Linzess may interact with antidiarrheal and ...

Linzess (linaclotide) is a prescription medication approved by the Food and Drug Administration (FDA) to treat certain types of constipation. Most Medicare Part D plans provide coverage for the drug ...

Linzess comes as a capsule that you swallow. Keep reading for details on Linzess and cost and how to save money on prescriptions. »LEARN MORE:For more details about this medication, check out this ...

Linzess may interact with anticholinergic drugs, such as oxybutynin (Ditropan XL), and antidiarrheal drugs, such as loperamide (Imodium). Taking these drugs with Linzess can make Linzess less ...